Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Protagonist Therapeutics (PTGX) Accumulated Depreciation & Amortization (2017 - 2025)

Protagonist Therapeutics' Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 18.19% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $8.3 million, up 18.19%, while the annual FY2025 figure was $8.3 million, 18.19% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $8.3 million at Protagonist Therapeutics, up from $7.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.3 million in Q4 2025 and bottomed at $4.3 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $6.6 million (2022), against an average of $6.3 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization decreased 12.91% in 2021 before it skyrocketed 56.48% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $4.3 million in 2021, then surged by 56.48% to $6.7 million in 2022, then dropped by 6.44% to $6.2 million in 2023, then grew by 12.85% to $7.0 million in 2024, then rose by 18.19% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Accumulated Depreciation & Amortization are $8.3 million (Q4 2025), $7.9 million (Q3 2025), and $7.6 million (Q2 2025).